These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19773200)

  • 1. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.
    Kan T; Meltzer SJ
    Curr Opin Pharmacol; 2009 Dec; 9(6):727-32. PubMed ID: 19773200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim.
    Kan T; Sato F; Ito T; Matsumura N; David S; Cheng Y; Agarwal R; Paun BC; Jin Z; Olaru AV; Selaru FM; Hamilton JP; Yang J; Abraham JM; Mori Y; Meltzer SJ
    Gastroenterology; 2009 May; 136(5):1689-700. PubMed ID: 19422085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study.
    Revilla-Nuin B; Parrilla P; Lozano JJ; de Haro LF; Ortiz A; Martínez C; Munitiz V; de Angulo DR; Bermejo J; Molina J; Cayuela ML; Yélamos J
    Ann Surg; 2013 May; 257(5):886-93. PubMed ID: 23059500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
    Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
    Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.
    Fang Y; Chen X; Bajpai M; Verma A; Das KM; Souza RF; Garman KS; Donohoe CL; O'Farrell NJ; Reynolds JV; Dvorak K
    Ann N Y Acad Sci; 2013 Oct; 1300():187-199. PubMed ID: 24117642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
    Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
    Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
    Streppel MM; Pai S; Campbell NR; Hu C; Yabuuchi S; Canto MI; Wang JS; Montgomery EA; Maitra A
    Clin Cancer Res; 2013 Aug; 19(15):4067-78. PubMed ID: 23757351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
    Maru DM; Singh RR; Hannah C; Albarracin CT; Li YX; Abraham R; Romans AM; Yao H; Luthra MG; Anandasabapathy S; Swisher SG; Hofstetter WL; Rashid A; Luthra R
    Am J Pathol; 2009 May; 174(5):1940-8. PubMed ID: 19342367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
    Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
    Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and clinical implementation of biomarkers for Barrett's esophagus.
    Varghese S; Lao-Sirieix P; Fitzgerald RC
    Gastroenterology; 2012 Mar; 142(3):435-441.e2. PubMed ID: 22266150
    [No Abstract]   [Full Text] [Related]  

  • 18. Myo9B is associated with an increased risk of Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; Van Zoest KP; Moons LM; Pot RG; Siersema PD; Kuipers EJ; Kusters JG
    Scand J Gastroenterol; 2012 Dec; 47(12):1422-8. PubMed ID: 22954106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology of Barrett's esophagus and esophageal adenocarcinoma.
    Wang DH; Souza RF
    Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):25-38. PubMed ID: 21112495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
    Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
    J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.